Delivra Corp’s Cannabinoid Therapy Could Pay Off Big


Delivra Corp. (TSXV:DVA) is well positioned with its growing revenues and could generate positive cash flow from operations in the near-term

SmallCapPower | January 30, 2018: Delivra Corp. (TSXV:DVA) is a specialty biotechnology company specializing in a transdermal delivery system platform. Its proprietary technology can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Some of the major benefits of transdermal therapeutics over traditional pills are that Delivra’s products are fast-acting, improved efficacy and target

...read more at https://smallcappower.com/analyst-articles/delivra-corps-cannabinoid-therapy-pay/

by